BioLife Solutions, Inc. (NASDAQ:BLFS) Stock Position Lowered by Russell Investments Group Ltd.

Russell Investments Group Ltd. cut its holdings in shares of BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 38.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 272,262 shares of the medical equipment provider's stock after selling 169,966 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.59% of BioLife Solutions worth $7,068,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in BLFS. Steward Partners Investment Advisory LLC acquired a new stake in shares of BioLife Solutions during the fourth quarter worth approximately $26,000. 1620 Investment Advisors Inc. grew its holdings in BioLife Solutions by 41.7% during the 4th quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider's stock worth $60,000 after acquiring an additional 675 shares in the last quarter. Smartleaf Asset Management LLC increased its position in shares of BioLife Solutions by 27.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 4,469 shares of the medical equipment provider's stock worth $117,000 after purchasing an additional 950 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of BioLife Solutions in the 4th quarter valued at about $171,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in shares of BioLife Solutions in the 4th quarter valued at about $201,000. 93.24% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at BioLife Solutions

In related news, CMO Todd Berard sold 1,577 shares of the company's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $25.00, for a total value of $39,425.00. Following the completion of the sale, the chief marketing officer now owns 104,961 shares of the company's stock, valued at $2,624,025. This represents a 1.48 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Aby J. Mathew sold 1,597 shares of the firm's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $25.00, for a total transaction of $39,925.00. Following the transaction, the executive vice president now directly owns 260,601 shares in the company, valued at approximately $6,515,025. The trade was a 0.61 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 72,127 shares of company stock worth $1,676,533. 2.20% of the stock is owned by company insiders.

Remove Ads

BioLife Solutions Stock Performance

NASDAQ:BLFS traded up $0.35 during midday trading on Tuesday, reaching $22.43. 438,383 shares of the company traded hands, compared to its average volume of 375,368. BioLife Solutions, Inc. has a twelve month low of $14.84 and a twelve month high of $29.55. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. The company has a fifty day moving average price of $24.87 and a 200 day moving average price of $25.31. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of -21.16 and a beta of 1.93.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last announced its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.32. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. The company had revenue of $22.71 million during the quarter, compared to the consensus estimate of $21.73 million. During the same quarter in the previous year, the company posted ($0.21) earnings per share. On average, analysts expect that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

Wall Street Analyst Weigh In

BLFS has been the subject of several research analyst reports. Northland Securities boosted their price objective on BioLife Solutions from $28.00 to $31.00 and gave the company an "outperform" rating in a report on Wednesday, January 8th. HC Wainwright lifted their target price on BioLife Solutions from $27.00 to $30.00 and gave the stock a "buy" rating in a research report on Thursday, March 6th. StockNews.com raised BioLife Solutions from a "sell" rating to a "hold" rating in a research report on Tuesday, April 8th. Finally, Benchmark reaffirmed a "buy" rating and issued a $30.00 price objective on shares of BioLife Solutions in a report on Thursday, December 19th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $31.17.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.